Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Evaggelos G. Papasteriadis"'
Autor:
Fotios G. Kardaras, Dimitri J. Richter, Pavlos Toutouzas, Stefanos G. Foussas, Evaggelos G. Papasteriadis, Michalis N. Zairis, Christodoulos Stefanadis, Paraskeui G. Vogiatzi, John Gialafos, George Andrikopoulos, R.K. Mattu, Gemig study investigators, Edward W. Needham, Elias Gialafos, Stylianos E. Tzeis
Publikováno v:
European Journal of Cardiovascular Prevention & Rehabilitation. 11:477-483
BackgroundThe insertion/deletion polymorphism of the angiotensin-converting enzyme (ACE) and the A1166C polymorphism of the angiotensin-II AT1 receptor (AT1R) have been extensively investigated as possible risk factors for myocardial infarction (MI).
Autor:
Alexandros S, Stefanidis, Panagiotis N, Margos, Athanasios A, Kotsakis, Evaggelos G, Papasteriadis
Publikováno v:
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese. 50(4)
Myocardial perforation is a rare complication of permanent pacemaker insertion and is usually detected during the first month after implantation. Pericardial effusion often occurs at the same time, and as a consequence may generate difficulties in th
Autor:
George K. Andrikopoulos, Dimitri J. Richter, Edward W. Needham, Stylianos E. Tzeis, Michalis N. Zairis, Elias J. Gialafos, Paraskeui G. Vogiatzi, Evaggelos G. Papasteriadis, Fotios G. Kardaras, Stefanos G. Foussas, John E. Gialafos, Christodoulos I. Stefanadis, Pavlos K. Toutouzas, Raj K. Mattu
Publikováno v:
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on EpidemiologyPrevention and Cardiac Rehabilitation and Exercise Physiology. 11(6)
The insertion/deletion polymorphism of the angiotensin-converting enzyme (ACE) and the A1166C polymorphism of the angiotensin-II AT1 receptor (AT1R) have been extensively investigated as possible risk factors for myocardial infarction (MI).Genetic as
Publikováno v:
European Heart Journal. 28:2552-2553
We have read with interest and became aware of diverse therapeutic approaches in several recently published guidelines, referring to patients with prosthetic heart valves and atrial fibrillation.1–3 In the latest European guidelines on the manageme